Results 121 to 130 of about 28,931 (239)

Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy [PDF]

, 2002
We studied bone mineral density (BMD), bone metabolism, and body composition in 47 children with central precocious puberty (n = 36) or early puberty (n = 11) before, during, and after cessation of GnRH agonist.
Boot, A.M. (Annemieke), Drop, S.L.S. (Stenvert), Krenning, E.P. (Eric), Muinck Keizer-Schrama, S.M.P.F. (Sabine) de, Sluis, I.M. (Inge) van der   +4 more
core  

Successful pregnancy via assisted reproductive technology following combined high-intensity focused ultrasound, ethanol injection, and GnRH agonist therapy for refractory uterine fibroids: a case report

International Journal of Hyperthermia
Background Refractory and recurrent uterine fibroids present complex therapeutic challenges, particularly in patients who desire fertility preservation.
Qi Wan, Qingling Wang, Xue Jiao Wang, Xiaoli Wang   +3 more
doaj   +1 more source

Pattern of prolactin secretion after administration of gonadotropin-releasing hormone agonist at the preovulatory phase of intrauterine insemination cycles

São Paulo Medical Journal
CONTEXT AND OBJECTIVE: Administration of a gonadotropin-releasing hormone (GnRH) agonist at the preovulatory phase is an option for triggering ovulation in assisted reproductive technology cycles.
Mario Cavagna, João Carlos Mantese, Gilberto da Costa Freitas, Artur Dzik, Jonathas Borges Soares, Yaron Hameiry, Vicente Mario Izzo, José Aristodemo Pinotti   +7 more
doaj   +1 more source

A pituitary adenoma secreting high molecular weight adrenocorticotropin without evidence of Cushing's disease [PDF]

, 1987
Allolio, B., Kaulen, D., Reincke, Martin, Saeger, W., Winkelmann, W.   +4 more
core   +1 more source

Improvement in Myoclonus-Dystonia Syndrome during Treatment with Gonadotropin-Releasing Hormone Agonist. [PDF]

Mov Disord Clin Pract, 2023
Moura J, Magalhães M.
europepmc   +1 more source

Six-month gonadotropin releasing hormone (GnRH) agonist depots provide efficacy, safety, convenience, and comfort

Cancer Management and Research, 2011
E David Crawford, Jason M PhillipsUniversity of Colorado Health Sciences Center, Aurora, CO, USAAbstract: Two different 6-month GnRH agonist depot formulations approved for palliative treatment of advanced and metastatic prostate cancer in the United ...
Phillips JM, Crawford ED
doaj  

Pituitary Apoplexy Secondary to Gonadotropin-Releasing Hormone Agonist for Breast Cancer. [PDF]

JCEM Case Rep, 2023
Mastandrea K, Voica M, Tetlay M, Hasan F.   +3 more
europepmc   +1 more source

Fresh versus frozen embryo transfer after gonadotropin-releasing hormone agonist trigger in gonadotropin-releasing hormone antagonist cycles among high responder women: A randomized, multi-center study

International Journal of Reproductive BioMedicine, 2018
Background: The use of embryo cryopreservation excludes the possible detrimental effects of ovarian stimulation on the endometrium, and higher reproductive outcomes following this policy have been reported.
Abbas Aflatoonian, Mahnaz Mansoori-Torshizi, Maryam Farid Mojtahedi, Behrouz Aflatoonian, Mohammaad Ali Khalili, Mohammad Hossein Amir-Arjmand, Mehrdad Soleimani, Nastaran Aflatoonian, Homa Oskouian, Nasim Tabibnejad, Peter Humaidan   +10 more
doaj  

Rapidly growing extensive polypoid endometriosis after gonadotropin-releasing hormone agonist discontinuation: A case report. [PDF]

World J Clin Cases, 2023
Zhang DY, Peng C, Huang Y, Cao JC, Zhou YF.   +4 more
europepmc   +1 more source

Gonadotropin-Releasing Hormone Agonist [PDF]

, 2008
openaire   +1 more source